OphSourceHomeJournal CollectionOphSource ShopEvents
Journal Home
Search for

Volume 112, Issue 4, Pages 593-598 (April 2005)


View previous. 11 of 47 View next.

Intraocular Pressure Elevation After Intravitreal Triamcinolone Acetonide Injection

Jost B. Jonas, MDCorresponding Author Informationemail address, Robert F. Degenring, MD, Ingrid Kreissig, MD, Imren Akkoyun, MD, Bernd A. Kamppeter, MD

Received 15 July 2004; accepted 15 October 2004.

Purpose

To report on intraocular pressure (IOP) after intravitreal injections of triamcinolone acetonide.

Design

Meta-analysis of previously reported data and case series studies.

Participants

The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months).

Intervention

Intravitreal injection of approximately 20 mg triamcinolone acetonide.

Main Outcome Measure

Intraocular pressure.

Results

Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age (P = 0.029) was significantly associated with triamcinolone-induced ocular hypertension. Triamcinolone responders and triamcinolone nonresponders did not vary significantly in gender (P = 0.42), refractive error (P = 0.86), diabetes mellitus status (P = 0.74), and reason for treatment.

Conclusions

These findings may be useful for comparing risks and benefits of intravitreal triamcinolone acetonide therapy.

Department of Ophthalmology, Faculty of Clinical Medicine Mannheim of the University Heidelberg, Heidelberg, Germany

Corresponding Author InformationCorrespondence to J. Jonas, MD, Universitäts-Augenklinik, Theodor-Kutzer-Ufer 1-3, 68167 Mannheim, Germany

 Manuscript no. 240564.

PII: S0161-6420(04)01787-7

doi:10.1016/j.ophtha.2004.10.042


View previous. 11 of 47 View next.